Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-11-13
2010-12-07
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S318000, C514S333000, C514S341000, C544S364000, C546S194000, C546S256000, C546S274100
Reexamination Certificate
active
07846933
ABSTRACT:
The present invention relates to a compound of the formula [I]:wherein G1is an alkyl which is substituted by a halogen atom or an alkoxy, or a group of the formula:wherein ring B is benzene ring which may be substituted, etc., Q1 and Q2 may be the same or different, and each is hydrogen atom, a halogen atom or an alkyl, n is 0, 1, 2, 3 or 4, R1is hydrogen atom, an alkyl which may be substituted, a cycloalkyl which may be substituted, a phenyl which may be substituted, etc., Z1, Z2, Z3and Z4may be the same or different, and each is CH or N, provided that 3 or more of Z1, Z2, Z3and Z4should not be N at the same time, G2is hydrogen atom, —NR3R4, —OR5, etc., where R3to R8each is independently hydrogen atom, an alkyl which may be substituted, an alkenyl, an alkynyl, etc., or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 3538104 (1970-11-01), Gruenfeld
patent: 4532250 (1985-07-01), Stout et al.
patent: 6329526 (2001-12-01), Adams et al.
patent: 6566357 (2003-05-01), Laufersweiler et al.
patent: 6579874 (2003-06-01), Revesz et al.
patent: 6677337 (2004-01-01), Laufersweiler et al.
patent: 6730668 (2004-05-01), Clark et al.
patent: 7473695 (2009-01-01), Kubo et al.
patent: 2003/0105084 (2003-06-01), Clark et al.
patent: 1180518 (2002-02-01), None
patent: 1205478 (2002-05-01), None
patent: 10-291982 (1998-04-01), None
patent: WO 02/076974 (2002-10-01), None
patent: WO 03/035638 (2003-05-01), None
Robert W. Carling, et al., “1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1,3-dihydroimidazol-2-one: A Selective High-Affinity Antagonist for the Human Dopamine D4Receptor with Excellent Selectivity over Ion Channels”,J. Med. Chem. 1999, 42, 2706-2715.
Winton D. Jones, Jr., et al., “The Synthesis and Biological Activity of Pyridyl-2(3H)-Oxazolones”,Proceedings: NOBCChE '94, vol. 21, Aug. 1994., 100-115.
Jeffrey C. Boehm & Jerry L. Adams, “Expert Opinion on Therapeutic Patents, ”New inhibitors of p38 kinase,Ashley Publications Ltd., ISSN 1354-3776 (2000), 25-37.
Stephen E. deLaszlo et al., “Pyrroles and Other Heterocycles as Inhibitors of P38 Kinase”,Bioorganic&Medicinal Chemistry Letters8 (1998) 2689-2694.
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1992-1996, 1996.
Simone, Oncology: Introduction, Cecil Textbook of Medicnine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Kubo et al., CAPLUS Abstract 138:353990, 2003.
Hiramatsu Hajime
Imashiro Ritsuo
Kubo Akira
Miyoshi Hidetaka
Nakajima Tatsuo
Birch & Stewart Kolasch & Birch, LLP
Mitsubishi Tanabe Pharma Corporation
Rao Deepak
LandOfFree
4-imidazolin-2-one compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-imidazolin-2-one compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-imidazolin-2-one compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4220366